Molecular biology of dissemination in bladder cancer laboratory findings and clinical significance

World Journal of Urology

Volumn 14, Issue 3, 1996, Pages 190-196

  Schmitz Drager B J ^a   Jankevicius, F ^a   Ackermann, R ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BASEMENT MEMBRANE; BLADDER TUMOR; CELL ADHESION; CELL MOTION; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PATHOLOGY; PERMEABILITY; PHYSIOLOGY; REVIEW; VASCULARIZATION;

ANIMALS; BASEMENT MEMBRANE; CELL ADHESION; CELL MOVEMENT; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PERMEABILITY; URINARY BLADDER NEOPLASMS;

EID: 0029681808     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Abou-Farha KM, Menheere PP, Nieman FH, Janknegt RA, Arenas JW (1993) Relation between basement membrane degradation and serum levels of laminin PI in patients with transitional cell carcinoma of the bladder. Urol Int 50: 13-16
2. Abou-Farha KM, Menheere PP, Nieman FH, Janknegt RA, Arends JW (1993) Urine laminin assessment discriminates between invasive and noninvasive urothelial carcinoma of the bladder. Urol Int 51 :204-208
3. Banks RE, Gearing AJH, Hemingway IK, Norfolk DR, Perren TJ, Selby PJ (1993) Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68: 122-124
4. Boyer B, Vallès AM, Tucker GC, Delouvee A, Thiery JP (1993) Involvement of cell motility in tumor progression. Symp Soc ExpBiol 47:183-195
5. Bringuier PB, Umbas R, Schaafsma HE, Karthaus HFM, Debruyne FMJ, Schalken JA (1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53:3241-3245
6. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau E, Dvorak HF, Senger D (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143 : 1255-1262
7. Chopin DK, Caruelle J-P, Colombie M, Palcy S, Ravery V, Caruelle D, Abbou CC, Barritault D (1993) Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 150: 1126-1 130
8. Chow N-H. Tzai T-S, Lin S-N, Chan S-H, Tang M-J (1993) Reappraisal of the biological role of epidermal growth factor receptor in transitional cell carcinoma. Eur Urol 24:140-143
9. Connolly DT. Heuvelman DM, Nelson R, Olander JV, Eppley BL. Delfino JJ, Siegel NR, Leimgruber RM, Feder J (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478
10. Cordon-Cardo C. Wartinger D, Petrylak D, Dalbagni G, Fair WR. Fuks Z. Reuter VE (1992) Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251-1261
11. 1. Craft PS, Harris AL (1994) Clinical prognostic significance of tumour angiogenesis. Ann Oncol 5:305-31 1
12. Dalbagni G, Presti JC. Reuter VE, Zhang ZF, Sarkis AS, Fair WR. Cordon-Cardo C (1993) Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 2:4-13
13. Ding-Wei Y, Jia-FiTz. Song-Xi Q. Yong-Jiang M (1993) Correlation between the expression of oncogenes ras and c-erbB2 and the biological behavior of bladder tumors. Urol Res 21 : 39-43
14. Esrig D, Elmajian D, Groshen S. Freeman JA, Stein JP, Chen SC. Nichols PW, Skinner DC, Jones PA, Cote RJ (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 : 1259-1264
15. Folkman J. Shing Y (1992) Angiogenesis. J Biol Chem 267: 10931-10934
16. Fossa SD. Berner AA, Jacobsen AB, Waehre H, Kvarstein B, Urnes T, Ogreid P, Johansen TE, Silde J, Nesland JM, Pettersen EO (1992) Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein and HCG in operable muscle-invasive bladder cancer. Br J Cancer 68:572-578
17. Fradet Y. Lafleur L, LaRue H (1992) Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder. J Cell Biochem [Suppl] 161:85-92
18. Fujimoto K, Yamada Y, OkajimaE. Kakizoe T, Sasaki H, Sugimura T, Terada M (1992) Frequent association of p53 mutations in invasive bladder cancer. Cancer Res 52:1393-1398
19. Fujita S. Suzuki H. Kinoshita M, Hirohashi S ( 1992) Inhibition of cell attachment, invasion and metastasis of human carcinoma cells by anti-integrin B1 subunit antibody. Jpn J Cancer Res 83:1317-1326
20. Gardiner RA, Samaratungu MLTH. Walsh MD, Seymour GJ, Lavin MF (1992) An immunohistological demonstration of reiiiB-2 oncoprotein expression in primary urothelial bladder cancer. Urol Res 20: 117-120
21. Gavrilovic J, Moens G, Thiery JP, Jouanneau J (1990) Expression of transfected transforming growing factor a induces a motile fibroblast-like phenotype with extracellular matrix-degrading potential in a rat bladder carcinoma cell line. Cell Regul 1:1003
22. Goodrich DW. Chen Y, Scully P, Lee WH (1992) Expression of the retinoblastoma gene product in bladder carcinoma cells associates with a low frequency of tumor formation. Cancer Res 52:1968-1973
23. Gordon J. Shu WP, Schlüssel RN, Droller MJ, Liu BCS (1993) Altered extracellular matrices influence cellular processes and nuclear matrix organisations of overlying human bladder urothelial cells. Cancer Res 53:4971-4977
24. Gray G, Hernandez O, Hebel D, Root M, Pow-Sang JM, Wickstrom E ( 1993) Antisense DNA inhibition of tumor growth induced by r-Has-ras oncogene in nude mice. Cancer Res 53 : 577-580
25. Javadpour N, Guirguis R (1991) Tumor collagenase stimulating factor (TCSF) and tumor autocrine motility factor (TAMF) in bladder cancer. Prog Clin Biol Res 370:393-398
26. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stocken E. Day RS III, Johnson BE, Scolnick MH ( 1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440
27. Kinsella AR, Lepts GC, Hill CL, Jones M (1994) Reduced E-cadherin expression correlates with increased invasiveness in colorectal carcinoma cell lines. Clin Exp Metastasis 12: 335-342
28. Knowles MA, Williamson M (1993) Mutation of H-ra.v is infrequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 53:133-139
29. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306
30. Lieber! M, Washington R, Wedemeyer G, Carey TE, Grossman HB (1994) Loss of colocalization of a64 integrin and collagen VII in bladder cancer. Am J Pathol 144:787-795
31. Lieber! M, Washington R, Stein J, Wedemeyer G, Grossman HB (1994) Expression of the VLA l integrin family in bladder cancer. Am J Pathol 144: 1016-1022
32. Lipponen P (1993) Expression of c-ei'bB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 29:749-753
33. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 53:365-370
34. Lipponen PK, Eskelinen MJ (1992) Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. Br J Cancer 66: 171 -176
35. Makri D, Schulz WA, Grimm MO, Schmitz-Dräger BJ ( 1995) Rapid killing of urothelial carcinoma cells by wild-type p53. IntJOncol 7:637-641
36. Matsubara T, Saura R, Hirohata Z, Ziff M (1989) Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest 83: 158-167
37. Mickisch GH (1993) Current status and future directions of research on multidrug resistance. The impact of contemporary biotechnology. Urol Res 21:79-81
38. Mickisch GH, Schroeder FH (1994) From laboratory expertise to clinical practice: multidrug-resistance-based gene therapy becomes available for urologists. World J Urol 12: 104-111
39. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Hosaka M, Iwasaki Y. Danenberg K, Danenberg PV (1993) Analyses of p53 gene mutations in primary human bladder cancer. Oncol Res 5:245-249
40. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH III. Gonzalez-Zulueta G. Nichols PW, Skinner DC. Jones PA (1993) Role of chromosome 9 in human bladder cancer. Cancer Res 53:4066-4070
41. Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F. Waldman F ( 1993) P53 and i'rbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch [A] 423:329-334
42. Moriyama M, Akiyama T, Yamamoto T, Kawamoto T, Kalo T. Sato K, Watanuki T. Hikage T. Katsuta N. Mori S (1991) Expression of < -crbB-2 gene product in urinary bladder cancer. J Urol 145:423-427
43. Neal DE, Mellon K (1992) Epidermal growth factor receptor and bladder cancer: a review. Urol Int 48:365-371
44. Neal DE, Smith K, Fennelly JA, Bennet JK, Hall RR, Harris AL (1989) Epidermal growth factor receptor in bladder cancer: a comparison of immunohistochemistry and ligand binding. J Urol 141:517-521
45. Neal DE, Sharpless S, Smith K, Fennelly J, Hall RR, Harris AL (1990) The epidermal growth factor receptors and the prognosis of bladder cancer. Cancer 65:1619-1625
46. Offner FA. Schafer G, Hittmair A, Ofner D, Grunewald D, Weyrer K, Mattern D, Eberle J. Mikuz G, Feichtinger H (1993) [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder.! Verh Dtsch Ges Pathol 77: 241-246
47. Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O. Iwaguchi T, Hiragun A (1990) Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 178:247-250
48. Oka K, Ishikawa J, Bruner JM, Takahashi R, Saya H (1991) Detection of loss of heterozygosily in the p53 gene in renal carcinoma and bladder cancer using the polymerase chain reaction. Mol Carcinog 4: 10-13
49. Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rübeen H, Raz A (1994) Inverse relation of E-cadherin and autocrine motility factor receptor as a prognostic factor in patients with bladder carcinomas. Cancer Res 54:3120-3123
50. Reddy EP, Reynolds R. Santos E, Barbacid M (1982) A point mutation is responsible for the acquisition of transforming properties in the T24 human bladder carcinoma oncogene. Nature 300:149-152
51. Roberts WO, Hasan T (1993) Tumor secreted vascular permeability factor/vascular endothelial growth factor influences photosensitizer uptake. Cancer Res 53:153-157
52. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85:53-59
53. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1994) Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 152:388-392
54. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, Okuhara E, Akiyama T, Toyoshima K, Yamamoto T, Kalo T (1992) An immunohistologic evaluation of c-erbB-2 gene production in patients with urinary bladder carcinoma. Cancer 70:2493-2498
55. Schmitz-Dräger BJ, Roeyen CR van, Grimm MO, Gerharz CD, Decken K, Schulz WA, Bültel H, Makri D, Ebert T, Ackermann R (1994) P53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol 12:79-83
56. Schmitz-Dräger BJ, Roeyen CR van, Gerharz C-D, Decken K, Bültel H, Schulz WA, Grimm M-O, Ebert T, Ackermann R (1995) P53 and c-myc während der Entstehung und Progression von Urotheltumoren. Aktuel Urol (in press)
57. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1987) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985
58. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709
59. Smith K, Fennelly JA, Neal DE, Hall RR, Harris AL (1989) Characterization and quantitation of the epidermal growth factor receptors in invasive and superficial bladder tumors. Cancer Res 49:5810-5815
60. oO.Soini Y, Turpeenniemi-Hujanen T, Kamel D, Autio-Harmainen H, Risteli J, Risteli L, Nuorva K, Pääkkö P, Vähäkangas K (1993) P53 immunohistochemistry in transitional cell carci-noma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 68:1029-1035
61. Spinardi L, Ren YL, Sanders R, Giancotti FG ( 1993 ) The beta 4 subunit cytoplasmic domain mediates the interaction of alpha 6 beta 4 integrin with the cytoskeleton of hemidesmosoines. Mol Biol Cell 4:871-884
62. Spruck CH III, Gonzales ZM, Shibata A, Simoneau AR. Lin MF. Gonzales F, Tsai YC, Jones PA (1994) P16 gene in uncultured tumours. Nature 370:180
63. Tabin CJ, Bradley SM, Bargmann Cl. Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR, Chang EH ( 1982) Mechanism of activation of a human oncogene. Nature 300:143-148
64. Timpl R, Engle J, Martin GR (1983) Larninin - a multifunctional protein of basement membranes. Trends Biochem Sci 8: 207-209
65. Tomita Y. Watanabe H, Kobayashi H, Nishiyama T, Tsuji S, Imai K, Abo T, Fujiwara M, Sato S (1993) Expression of intercellular adhesion molecule-1 on transitional cell cancer. Am JPathol 143:191-198
66. Vallès AM, Boyer B, Badet J, Tucker GC, Barritault D, Thiery JP ( 1990) Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc Natl AcadSci USA 87:1124-1128
67. Vandenbunder B, Pardanaud L, Jaffredo T, Mirabel MA, Stehelin D (1989) Complementary patterns of expression of cetsl, c-myb and c-myc in the blood forming system of the chick embryo. Development 107:265-274
68. Viola MV, Fromowitz F, Gravez S, Deb S, Schlom J (1985) Ras oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med 161:1213
69. Wernert N, Raes MB, Lassalle PH, Dehouck MP, Gosselin B, Vandenbunder B, Stehelin D (1992) C-ets\ proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularisation and other forms of angiogenesis in humans. Am J Pathol 140: 119-127
70. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Home CH, Neal DE (1991) Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 63:967-970
71. Xu H-J, Cairns P, Hu S-X, Knowles MA, Benedict WF (1993) Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 53:781-784
72. Yamashita T, Sakai M, Kawai Y, Aono M, Takahashi K (1989) A new activity of herbimycin A: inhibition of angiogenesis. J Antibiot(Tokyo) 42:1015-1017
73. Yamazaki K, Kumamoto Y, Tsukamoto T (1993) Expression of squamous cell carcinoma-associated antigen in grade 3 pT 1 transitional cell carcinoma of the bladder and prediction of its progression and intravesical recurrence. Cancer 72:3676-3684